Business Context and Reporting Period
Company: NeOnc Technologies Holdings, Inc. (NTHI)
Filing Type: Form 8-K (Current Report)
Date of Report: December 1, 2025
Reporting Period: Events occurring on December 1, 2025
Business Overview: The Company is an emerging growth company incorporated in Delaware, trading on the Nasdaq Capital Market. This filing reports a material definitive agreement for a private placement of equity and the disclosure of preclinical research findings.
Key Financial Metrics
Capital Raised: Approximately $1 million from the sale of 111,732 shares of common stock.
Share Price: $8.95 per share (based on the closing price on November 28, 2025).
Use of Proceeds: Working capital.
Other Metrics: The filing does not provide specific data on revenue, profit, cash flow, margins, debt, or liquidity positions for the period.
Material Changes
- Equity Issuance: The Company entered into a Securities Purchase Agreement with investor Saad Naja to issue 111,732 shares of common stock.
- Regulatory Status: The shares were sold pursuant to an exemption from registration requirements under Section 4(a)(2) of the Securities Act of 1933.
- Future Filing Obligation: The Company is required to file a resale registration statement for these shares within ten (10) days of the agreement date.
Guidance, Outlook, and Management Commentary
Scientific Developments: On December 1, 2025, the Company issued a press release announcing newly published preclinical findings from a research collaboration at the University of Southern California. This information is furnished under Regulation FD but is not deemed "filed" for liability purposes under the Exchange Act.
Management Commentary: The filing does not contain specific forward-looking financial guidance or management commentary regarding future earnings or operational targets beyond the stated use of proceeds for working capital.
Investor Verification Checklist
- Verify the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants, representations, and conditions to closing.
- Review the press release (Exhibit 99.1) for details on the preclinical findings from the University of Southern California collaboration.
- Confirm the filing of the resale registration statement within the required ten-day window following December 1, 2025.
- Monitor subsequent filings for updated financial statements to assess the impact of the $1 million capital raise on liquidity and working capital.